Guangxi LiuYao Group Co., Ltd (603368.SS)
CNY 18.49
(-0.59%)
CNY 18.49
(-0.59%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.28 Billion CNY | 11.93% |
| 2022 | 1.13 Billion CNY | 20.56% |
| 2021 | 961.12 Million CNY | -2.32% |
| 2020 | 1.02 Billion CNY | 6.48% |
| 2019 | 1.07 Billion CNY | 43.98% |
| 2018 | 711.74 Million CNY | 39.2% |
| 2017 | 536.47 Million CNY | 26.92% |
| 2016 | 433.92 Million CNY | 37.06% |
| 2015 | 282.75 Million CNY | 14.91% |
| 2014 | 227.26 Million CNY | 23.35% |
| 2013 | 193.06 Million CNY | 35.29% |
| 2012 | 141.79 Million CNY | 30.14% |
| 2011 | 126.9 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 253.18 Million CNY | -41.89% |
| 2024 Q3 | 345.76 Million CNY | 36.56% |
| 2024 Q1 | 476.03 Million CNY | 46.11% |
| 2023 Q3 | 346.26 Million CNY | 1.83% |
| 2023 Q1 | 393.75 Million CNY | 39.5% |
| 2023 Q2 | 340.02 Million CNY | -13.65% |
| 2023 Q4 | 298.2 Million CNY | -13.88% |
| 2023 FY | - CNY | 11.93% |
| 2022 Q3 | 289.22 Million CNY | 0.26% |
| 2022 Q1 | 348.81 Million CNY | 97.51% |
| 2022 FY | - CNY | 20.56% |
| 2022 Q4 | 282.25 Million CNY | -2.41% |
| 2022 Q2 | 288.46 Million CNY | -17.3% |
| 2021 Q3 | 252.63 Million CNY | 1.34% |
| 2021 Q1 | 322.23 Million CNY | 51.11% |
| 2021 FY | - CNY | -2.32% |
| 2021 Q2 | 249.29 Million CNY | -22.64% |
| 2021 Q4 | 176.6 Million CNY | -30.1% |
| 2020 Q3 | 310.4 Million CNY | -4.97% |
| 2020 Q4 | 213.24 Million CNY | -31.3% |
| 2020 FY | - CNY | 6.48% |
| 2020 Q1 | 293.21 Million CNY | 27.72% |
| 2020 Q2 | 326.64 Million CNY | 11.4% |
| 2019 Q3 | 293.2 Million CNY | -6.7% |
| 2019 Q2 | 314.25 Million CNY | 26.5% |
| 2019 Q1 | 248.41 Million CNY | 27.66% |
| 2019 FY | - CNY | 43.98% |
| 2019 Q4 | 229.57 Million CNY | -21.7% |
| 2018 Q4 | 194.59 Million CNY | 1.29% |
| 2018 Q3 | 192.11 Million CNY | 5.84% |
| 2018 FY | - CNY | 39.2% |
| 2018 Q2 | 181.52 Million CNY | 2.43% |
| 2018 Q1 | 177.21 Million CNY | 41.2% |
| 2017 Q2 | 125.03 Million CNY | -7.83% |
| 2017 Q4 | 125.5 Million CNY | -15.22% |
| 2017 FY | - CNY | 26.92% |
| 2017 Q1 | 135.64 Million CNY | 7.62% |
| 2017 Q3 | 148.03 Million CNY | 18.4% |
| 2016 Q3 | 107.74 Million CNY | 5.22% |
| 2016 FY | - CNY | 37.06% |
| 2016 Q4 | 126.04 Million CNY | 16.98% |
| 2016 Q2 | 102.4 Million CNY | 3.66% |
| 2016 Q1 | 98.78 Million CNY | 50.04% |
| 2015 Q3 | 88.49 Million CNY | 13.66% |
| 2015 FY | - CNY | 14.91% |
| 2015 Q1 | 77.53 Million CNY | 32.64% |
| 2015 Q2 | 77.85 Million CNY | 0.42% |
| 2015 Q4 | 65.84 Million CNY | -25.6% |
| 2014 Q3 | 78.39 Million CNY | 6.6% |
| 2014 Q4 | 58.45 Million CNY | -25.44% |
| 2014 FY | - CNY | 23.35% |
| 2014 Q2 | 73.54 Million CNY | 16.04% |
| 2014 Q1 | 63.37 Million CNY | 21.97% |
| 2013 Q3 | 66.59 Million CNY | 0.0% |
| 2013 FY | - CNY | 35.29% |
| 2013 Q4 | 51.96 Million CNY | -21.98% |
| 2012 FY | - CNY | 30.14% |
| 2011 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| China Meheco Group Co., Ltd. | 2.27 Billion CNY | 43.482% |
| Liaoning Cheng Da Co., Ltd. | 465.75 Million CNY | -175.891% |
| Shanghai Pharmaceuticals Holding Co., Ltd | 11.24 Billion CNY | 88.573% |